Resbiotic Introduces resO, a Microbiome Supplement for Bone & Joint Health

A microbiome-centered formula applies resbiotic’s “Gut–Bone–Joint Axis” framework to mobility, aging and long-term musculoskeletal resilience

Resbiotic has launched resO Bone & Joint Support, extending the company’s microbiome-driven approach into musculoskeletal health. Positioned as an “osteobiotic,” resO is designed to support bone strength, joint comfort and everyday mobility by addressing both gut-mediated signaling and the downstream systems involved in movement.

The launch comes as bone and joint health is increasingly discussed in the context of longevity, activity and healthy aging rather than short-term pain management. Joint discomfort and mobility limitations remain a leading cause of disability in the U.S., yet much of the category continues to focus on localized symptom relief. Resbiotic’s approach reflects a broader shift toward addressing underlying biological systems, particularly as research continues to link gut health, immune balance and inflammation to bone and joint outcomes.

Founded by physician-scientist Dr. C. Vivek Lal, resbiotic builds its formulations around what it calls the “Gut-X Axis,” a framework describing how gut-derived signals influence systems throughout the body. With resO, that framework is applied specifically to the Gut–Bone–Joint Axis.

“At resbiotic, we start with the science of the microbiome and follow its impact beyond the gut through what we call the Gut-X Axis,” Dr. Lal told Athletech News. “This framework reflects a growing body of research showing that gut-derived signals help regulate immune balance, inflammatory responses, metabolism and tissue support across multiple systems in the body.”

According to Lal, resO was developed to support musculoskeletal health by influencing those pathways upstream rather than focusing only on the joints themselves.

“ResO was developed to support musculoskeletal health by working along the Gut–Bone–Joint Axis, an interconnected pathway where microbial signals influence immune activity and the health of joints, bones and connective tissue,” he said. “Unlike formulas that focus only on localized joint ingredients, resO combines this targeted postbiotic signaling with clinically studied nutrients that support pathways involved in cartilage, connective tissue and bone metabolism.”

At the center of the formula is a patented postbiotic strain, Lactiplantibacillus plantarum RSB11, included at a 16 billion cell equivalent. Postbiotics, which are non-living microbial compounds, are gaining attention for their role in immune signaling and inflammatory balance without the stability challenges of live probiotics.

In resO, that postbiotic is paired with a blend of established bone and joint ingredients, including boswellia, curcumin, bromelain, vitamin D3, glucosamine sulfate, chondroitin sulfate and MSM. Together, the formulation is intended to support cartilage integrity, connective tissue comfort and bone metabolism while reinforcing gut-mediated immune resilience.

Lal said the product was designed to address a structural gap in the bone and joint category.

“Most joint formulas only focus on short-term comfort, rather than supporting the systems that influence long-term bone and joint health,” he said. “Instead of targeting joints alone, resO works along the Gut–Bone–Joint Axis, supporting microbiome-immune balance while also supporting healthy inflammatory responses.”

The company is positioning resO for use across life stages rather than solely for older consumers. Lal noted that joint health is not exclusively an aging issue, pointing to active adults in their thirties and forties who are managing training loads, travel demands and everyday wear while trying to preserve mobility over time.

ResO joins resbiotic’s existing lineup, which includes resB, resG, resW and resM, and continues the company’s emphasis on physician-led formulation, full-formula clinical validation and third-party testing. The supplement is available direct-to-consumer for $35.

In September, resbiotic raised $14.5 million to expand its product lineup, including creating a flagship product for lung health.